A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Exclusion Criteria

• •Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 2 weeks prior to the first dose of ADA-011
• •Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to the first dose of ADA-011
• •Major trauma or major surgery within 4 weeks prior to the first dose of ADA-011
• •AEs from prior anticancer therapy that have not resolved to Grade ≤1 except for alopecia
• •Known, central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity.
• •Evidence of active uncontrolled viral, bacterial, or systemic fungal infection
• •Active SARS-CoV-2 infection, irrespective of symptoms.
• •History or risk of severe, chronic, untreated, or currently active autoimmune disease
• •Prior solid organ transplant or has had an allogenic hematopoietic stem cell transplant within the past 20 years
• •Pregnant, lactating, or breastfeeding